Showing results (161-170 of 3,361) with videos related to

Sort By:
Pageof 337
The Journal of Antimicrobial Chemotherapy|October 3, 2001
Evaluation of daptomycin susceptibility testing by Etest and the effect of different batches of mediaP C Fuchs, A L Barry, S D Brown
Antimicrobial Agents and Chemotherapy|May 17, 2001
In vitro activities of three nonfluorinated quinolones against representative bacterial isolatesA L Barry, P C Fuchs, S D Brown
Antimicrobial Agents and Chemotherapy|September 15, 2001
In vitro activity of the ketolide ABT-773A L Barry, P C Fuchs, S D Brown
Diagnostic Microbiology and Infectious Disease|July 1, 1993
Evaluation of disk susceptibility testing of fosfomycin tromethamineM A Pfaller, A L Barry, P C Fuchs
Journal of Clinical Microbiology|August 1, 1993
Tentative interpretive criteria for disk diffusion susceptibility testing of sparfloxacinP C Fuchs, A L Barry, M A Pfaller
Diagnostic Microbiology and Infectious Disease|September 1, 1996
Tentative interpretive criteria for testing the susceptibility of Streptococcus pneumoniae to eight fluoroquinolonesP C Fuchs, A L Barry, S D Brown
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|December 24, 1997
In vitro activity of the new ketolide HMR 3004 compared to an azalide and macrolides against Streptococcus pneumoniae and Haemophilus influenzaeA L Barry, P C Fuchs, S D Brown
Antimicrobial Agents and Chemotherapy|May 21, 1998
In vitro activities of clinafloxacin against contemporary clinical bacterial isolates from 10 North American centersP C Fuchs, A L Barry, S D Brown
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|March 1, 1992
Spontaneously occurring staphylococcal mutants resistant to clinically achievable concentrations of ciprofloxacin and temafloxacinA L Barry, M A Pfaller, P C Fuchs
Diagnostic Microbiology and Infectious Disease|August 1, 1988
Multicenter in vitro evaluation of lomefloxacin (NY-198, SC-47111), including tests against nearly 7,000 bacterial isolates and preliminary recommendations for susceptibility testingR N Jones, K E Aldridge, A L Barry, et al.
Pageof 337